about
Efficacy of psychostimulant drugs for amphetamine abuse or dependenceChronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdalaA stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence.Influence of chronic amphetamine treatment and acute withdrawal on serotonin synthesis and clearance mechanisms in the rat ventral hippocampus.Pharmacological strategies for detoxification.5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians.Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine useBAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawalSerotonergic responses to stress are enhanced in the central amygdala and inhibited in the ventral hippocampus during amphetamine withdrawal.Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field studyWithdrawal symptoms in abstinent methamphetamine-dependent subjects.Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction effortsGlutamatergic neurometabolites during early abstinence from chronic methamphetamine abuse.Serotonin in the ventral hippocampus modulates anxiety-like behavior during amphetamine withdrawal.Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference.Relapse and Risk-taking among Iranian Methamphetamine Abusers Undergoing Matrix Treatment ModelAn Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.Protocol for a systematic review of psychological treatment for methamphetamine use: an analysis of methamphetamine use and mental health symptom outcomes.1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.Amphetamine withdrawal differentially affects hippocampal and peripheral corticosterone levels in response to stress.Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain.Acute pain management in patients with drug dependence syndrome.Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.
P2860
Q24198261-BC079C37-22F1-49E7-A42F-7D503ED4E92BQ28568006-94A62DFD-6AFF-4749-86D5-B8D949E07297Q30422718-CC3A2F27-517A-4E09-8474-12072B6F67C1Q30443535-5F46F769-67DE-4F8C-A282-1BA2D6908A04Q33582092-336AD201-AB0A-405D-AF8C-2674314D9E2FQ34142888-C2646646-FADD-400F-9D09-F7A9949E24F7Q34154090-822E72F7-5F17-4DEF-B730-D624AF2AC02DQ34277168-86FC6B52-2CFB-4D27-BB87-FD928914AF49Q34657040-FB5CBFEA-6BC5-4938-85AC-3023E00DB1F0Q34674809-FACADB8D-F71C-4408-A759-7BD9DF742D92Q34713806-C29BAE3E-EF41-487C-845B-E304287D7B56Q34767322-A8AA2B07-4796-44D4-BF16-9DA6DCC2F799Q35160984-3A6E7843-3117-4481-B2DF-E87413549039Q35179062-92030F77-1BAF-435F-A341-B7AF0BD41EC6Q35192386-128BE9F5-1091-4478-8323-DC1A67182620Q35206777-F86A8AD5-805B-47FE-9E5F-BAAF4EFDEF8BQ35235473-C802473A-5A53-4E5D-850F-DE5498EE50D3Q35747260-4FFEAB89-BAB7-434C-82EC-486B5FCFB180Q36812920-B5EE25DC-3F74-406D-9D92-58DDB93E40E1Q39293219-AFE8B87C-7F28-4418-AC5C-44D560CAB987Q42267653-82FFE14B-640E-4854-B3C7-FEFA70099F98Q42418144-4DA7EA5B-0440-425F-B462-A66E53FD7F08Q42540788-F9D5B9D0-43B7-4DCA-B5C5-9790EFAB1CB3Q42841373-3E70BBAE-E6B5-4AF1-969A-4B0A7DF38008Q47387524-93091A46-3EAF-4817-B914-1B2AFD342433Q47919097-BA80BBF3-E869-4B31-9EC9-F8416E7D9681Q49384652-38683800-D812-4785-907A-DA9953C4B24FQ51735563-F113784A-04D7-483E-8C9D-7742FAFF011E
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Treatment for amphetamine withdrawal
@ast
Treatment for amphetamine withdrawal
@en
Treatment for amphetamine withdrawal
@en-gb
Treatment for amphetamine withdrawal
@nl
type
label
Treatment for amphetamine withdrawal
@ast
Treatment for amphetamine withdrawal
@en
Treatment for amphetamine withdrawal
@en-gb
Treatment for amphetamine withdrawal
@nl
prefLabel
Treatment for amphetamine withdrawal
@ast
Treatment for amphetamine withdrawal
@en
Treatment for amphetamine withdrawal
@en-gb
Treatment for amphetamine withdrawal
@nl
P2093
P2860
P1476
Treatment for amphetamine withdrawal
@en
P2093
Keith Heinzerling
Walter Ling
P2860
P304
P356
10.1002/14651858.CD003021.PUB2
P407
P577
2009-04-15T00:00:00Z